Eli Lilly and Co.’s Ebglyss (lebrikizumab) becomes the latest U.S. entrant in the increasingly competitive atopic dermatitis space, following FDA approval of the IL-13-targeting antibody, which will ...

The FDA on Friday signed off on Eli Lilly ’s therapeutic antibody lebrikizumab for the treatment of moderate-to-severe atopic dermatitis. Lilly will market the therapy under the ...

The release of early-stage data on three oral weight loss drug candidates hints at which companies have the strongest hand, ...

In a report released today, Akash Tewari from Jefferies maintained a Buy rating on BioMarin Pharmaceutical (BMRN – Research Report), with ...

For example, Nuvalent, Viridian Therapeutics and Cabaletta Bio have each said they could see disruptions ... Large pharma companies also face risks. Eli Lilly has tapped WuXi Apptec to produce some of ...

Kyverna Therapeutics, Inc. (Kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell ...

Despite insufficient data, writing panel will give recommendations for preparation, transfer, and follow-up for youth with ...

GC Therapeutics has entered gameplay with the mission of unlocking a new generation of cell therapies, uploading with $75 ...

Find out more about six immunology companies that have recently raised impressive funds in the biotech industry.

Eli Lilly is still celebrating the FDA approval ... including Eisai's antibody-based E-2814 and small-molecule drugs from Annovis Bio (buntanetap), BioVie (bezisterim), and TauRx (HMTM).